Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Clinical Immunology
Published in: Journal of Clinical Immunology 5/2008

01-09-2008

Increased Granulysin Expression in Peripheral Blood Cells of Patients with Primary Biliary Cirrhosis and Its Clinical Implications

Authors: Cheng Qian, Sunxiao Chen, Dingkang Yao, Chuanyong Wu, Tingwang Jiang, Jinshan Ke, Ye Zhou, Mingli Gu, Bo Chen, Anmei Deng, Renqian Zhong

Published in: Journal of Clinical Immunology | Issue 5/2008

Login to get access

Abstract

Introduction

Granulysin is a cytotoxic molecule involved in cellular immune reactions.

Materials and methods

The levels of granulysin mRNA in the peripheral blood and serum granulysin of patients with primary biliary cirrhosis (PBC) were determined by quantitative polymerase chain reaction and enzyme-linked immunosorbent assay, respectively. The expression of granulysin mRNA and serum protein in PBC was increased compared to the controls.

Results

The expression of granulysin mRNA or serum protein showed close associations, respectively, with natural killer cell population in PBC patients. Serum granulysin was down-regulated by steroid and ursodeoxycholic therapy for PBC according to the improvement of severity of PBC. In addition, the expression of serum granulysin were related to serum total bilirubin and Mayo Clinic risk score. The serum granulysin reflected the cellular immune status of patients with PBC, and the expression correlated with the severity of PBC.

Conclusion

Therefore, there is a clinical benefit to monitoring granulysin as a biomarker of the prognosis of patients with PBC.
Literature
1.
Pena SV, Krensky AM. Granulysin, a new human cytolytic granule-associated protein with possible involvement in cell-mediated cytotoxicity. Semin Immunol 1997;9:117–25.PubMedCrossRef
2.
Jongstra J, Schall TJ, Dyer BJ, Clayberger C, Jorgensen J, Davis MM, Krensky AM. The isolation and sequence of a novel gene from a human functional T cell line. J Exp Med 1987;165:601–14.PubMedCrossRef
3.
Deng A, Chen S, Li Q, Lyu SC, Clayberger C, Krensky AM. Granulysin, a cytolytic molecule, is also a chemoattractant and proinflammatory activator. J Immunol 2005;174:5243–8.PubMed
4.
Kaspar AA, Okada S, Kumar J, Poulain FR, Drouvalakis KA, Kelekar A, et al. A distinct pathway of cell-mediated apoptosis initiated by granulysin. J Immunol 2001;167:350–6.PubMed
5.
Krensky AM, Clayberger C. Granulysin: a novel host defense molecule. Am J Transplant 2005;5:1789–92.PubMedCrossRef
6.
Ogawa K, Takamori Y, Suzuki K, Nagasawa M, Takano S, Kasahara Y, et al. Granulysin in human serum as a marker of cell-mediated immunity. Eur J Immunol 2003;33:1925–33.PubMedCrossRef
7.
Ochoa MT, Stenger S, Sieling PA, Thoma-Uszynski S, Sabet S, Cho S, et al. T-cell release of granulysin contributes to host defense in leprosy. Nat Med 2001;7:174–9.PubMedCrossRef
8.
Saigusa S, Ichikura T, Tsujimoto H, Sugasawa H, Majima T, Kawarabayashi N, et al. Serum granulysin level as a novel prognostic marker in patients with gastric carcinoma. J Gastroenterol Hepatol 2007;22:1322–7.PubMedCrossRef
9.
Nagasawa M, Isoda T, Itoh S, Kajiwara M, Morio T, Shimizu N, et al. Analysis of serum granulysin in patients with hematopoietic stem-cell transplantation: its usefulness as a marker of graft-versus-host reaction. Am J Hematol 2006;81:340–8.PubMedCrossRef
10.
Sakai M, Ogawa K, Shiozaki A, Yoneda S, Sasaki Y, Nagata K, Saito S. Serum granulysin is a marker for Th1 type immunity in pre-eclampsia. Clin Exp Immunol 2004;136:114–9.PubMedCrossRef
11.
He XS, Ansari AA, Ridgway WM, Coppel RL, Gershwin ME. New insights to the immunopathology and autoimmune responses in primary biliary cirrhosis. Cell Immunol 2006;239:1–13.PubMedCrossRef
12.
13.
Benhamou JP. Indications for liver transplantation in primary biliary cirrhosis. Hepatology 1994;20:11S–13S.PubMed
14.
Goudie BM, Burt AD, Macfarlane GJ, Boyle P, Gillis CR, MacSween RN, Watkinson G. Risk factors and prognosis in primary biliary cirrhosis. Am J Gastroenterol 1989;84:713–6.PubMed
15.
Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000;31:1005–13.PubMedCrossRef
16.
Di Liberto D, Buccheri S, Caccamo N, Meraviglia S, Romano A, Di Carlo P, et al. Decreased serum granulysin levels in childhood tuberculosis which reverse after therapy. Tuberculosis (Edinb) 2007;87:322–8.CrossRef
17.
Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989;10:1–7.PubMedCrossRef
18.
Kita H, Matsumura S, He XS, Ansari AA, Lian ZX, Van de Water J, et al. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest 2002;109:1231–40.PubMed
19.
Latinovic-Golic S, Walch M, Sundstrom H, Dumrese C, Groscurth P, Ziegler U. Expression, processing and transcriptional regulation of granulysin in short-term activated human lymphocytes. BMC Immunol 2007;8:9.PubMedCrossRef
20.
Johansson S, Hall H, Berg L, Hoglund P. NK cells in autoimmune disease. Curr Top Microbiol Immunol 2006;298:259–77.PubMedCrossRef
21.
Okada C, Akbar SM, Horiike N, Onji M. Early development of primary biliary cirrhosis in female C57BL/6 mice because of poly I:C administration. Liver Int 2005;25:595–603.PubMedCrossRef
22.
Panasiuk A, Prokopowicz D, Zak J. Peripheral blood T, B lymphocytes and NK cells in primary biliary cirrhosis. Rocz Akad Med Bialymst 2001;46:231–9.PubMed
23.
Musialik J, Petelenz M, Jastrzebski D, Ziora D, Kondera-Anasz Z, Mertas A, et al. Lymphocyte subsets in peripheral blood and bronchoalveolar lavage in patients with primary biliary cirrhosis. Med Sci Monit 2001;7(1):311–5.PubMed
24.
Chuang YH, Lian ZX, Tsuneyama K, Chiang BL, Ansari AA, Coppel RL, Eric Gershwin M. Increased killing activity and decreased cytokine production in NK cells in patients with primary biliary cirrhosis. J Autoimmun 2006;26:232–40.PubMedCrossRef
25.
Fracchia M, Secreto P, Tabone M, Zaffino C, Pera A, Galatola G. Serum interferon gamma in primary biliary cirrhosis: effect of ursodeoxycholic acid and prednisone therapy alone and in combination. Eur J Gastroenterol Hepatol 2000;12:463–8.PubMedCrossRef
26.
Metadata
Title
Increased Granulysin Expression in Peripheral Blood Cells of Patients with Primary Biliary Cirrhosis and Its Clinical Implications
Authors
Cheng Qian
Sunxiao Chen
Dingkang Yao
Chuanyong Wu
Tingwang Jiang
Jinshan Ke
Ye Zhou
Mingli Gu
Bo Chen
Anmei Deng
Renqian Zhong
Publication date
01-09-2008
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 5/2008
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-008-9207-2

Other articles of this Issue 5/2008

Journal of Clinical Immunology 5/2008 Go to the issue

OriginalPaper

Association of Graves’ Disease and Prevalence of Circulating IFN-γ-producing CD28− T Cells

OriginalPaper

IL1 Gene Cluster Polymorphisms and Its Haplotypes may Predict the Risk to Develop Invasive Pulmonary Aspergillosis and Modulate C-reactive Protein Level

OriginalPaper

Elevated Serum Anti-Saccharomyces cerevisiae, Anti-I2 and Anti-OmpW Antibody Levels in Patients with Suspicion of Celiac Disease

OriginalPaper

Differential Induction of Immunoregulatory Circuits of Phagocytic Cells by Gal/Gal NAc Lectin from Pathogenic and Nonpathogenic Entamoeba

OriginalPaper

IkBα Promoter Polymorphisms in Patients with Primary Sjögren’s Syndrome

OriginalPaper

The Dynamics of Articular Leukocyte Trafficking and the Immune Response to Self Heat-Shock Protein 65 Influence Arthritis Susceptibility
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits